Common anti-inflammatory may increase risk of diabetes

November 11, 2019

A commonly prescribed anti-inflammatory may increase the risk of diabetes after just one week of treatment, according to new findings presented at The Society for Endocrinology Annual Conference. Healthy men given doses of the drug comparable to those used to treat inflammatory disorders had changes in markers of blood sugar metabolism associated with an increased risk of developing diabetes. The study findings highlight the potential long-term health implications for people regularly taking these drugs and that medical professionals may need to consider and monitor the potential side-effects, to avoid future debilitating conditions.

Glucocorticoids (GCs) are one of the most commonly prescribed anti-inflammatories for conditions such as arthritis, asthma, allergies and adrenal insufficiency. GC treatment at high doses for a long duration is known to be associated with metabolic side-effects that may increase risk of diabetes and obesity but there are currently no studies examining the short-term effects of GCs at the more regularly prescribed, lower doses. As 2-3% of the UK population take GCs for conditions of varying severity, it is important to investigate whether these metabolic side-effects occur in lower dose, short-term therapy.

Dr Riccardo Pofi, from Sapienza University of Rome and Prof Jeremy Tomlinson from the University of Oxford, measured markers of metabolism in healthy men given commonly prescribed doses (10 and 15mg) of GCs (prednisolone) after just one week of treatment. Although commonly checked clinical and biochemical parameters such as fasting blood sugar levels, weight and general health was unaffected, changes in metabolic markers indicated that their blood sugar regulation was impaired.

"This is the first study to examine the very short-term metabolic effects of commonly prescribed doses of glucocorticoids on healthy men and indicates, that even at these lower doses, glucose metabolism is impaired, suggesting an increased risk of diabetes with continued treatment," Dr Pofi comments.

These novel findings not only highlight the importance of determining the best GC dose that balances effectiveness with potentially negative metabolic effects, but also that medical professionals should be more aware of these risks and may need to monitor them in patients both on short and longer-term therapy.

Dr Pofi says, "This suggests that we need to more accurately assess GC use in patients to prevent and reduce the undesired effects, especially in patients for which steroid treatment is essential for life."

Future larger studies are required to confirm these findings and improve our understanding of how they are caused. Dr Pofi now plans to investigate the metabolic effects of taking GCs alongside diabetes drugs, to assess whether the unwanted side effects of GCs can be reduced or prevented with combined treatment.
-end-
Conference abstract, observational study, human

Abstract

P242

Glucocorticoid treatment is associated with dose-dependent effects in healthy male volunteers
Riccardo Pofi, Ilaria Bonaventura, Nanthia Othonos, Thomas Marjot, Ahmed Moolla, Andrea M. Isidori, Leanne Hodson, Jeremy W. Tomlinson

OBJECTIVE: 2-3% of the population of the UK receive glucocorticoid(GC) therapy. Significant adverse effects are not confined to chronic use: recurrent short-course administration is associated with increased morbidity and mortality. Data about the cumulative dose responsible for drawbacks during GC treatment are still lacking. The aim of this study was to test the impact of 7 days of 10 or 15mg of Prednisolone on metabolism in healthy male volunteers.

METHODS: 16 healthy male volunteers were recruited from the Oxford Bio-Bank and divided into 2 age- and BMI-matched control groups as following: 6 volunteers received 10 mg of Prednisolone and 10 volunteers received 15 mg of Prednisolone for 7 days. Anthropometric and metabolic parameters were recorded and all patients underwent low dose hyperinsulinaemic-euglycaemic clamp(HEC), before(pre) and after(post) treatment. The main outcome measure was the M-value gathered from the HEC.

RESULTS: Age, BMI and fasting blood glucose were not different between the groups at baseline. After one week of prednisolone 10 or 15 mg, no differences were found in delta(Δ=post-pre) fasting glucose(FG) (median ΔFG15mg 0.15±0.36 nmol/L vs ΔFG10mg 0.15±0.36 nmol/L, p=0.635). However, M-value was significantly reduced in patients taking 15 mg of prednisolone (median ΔM15mg -2.5±2.0 mg/Kg/min vs ΔM10mg -0.4±1.3 mg/Kg/min, p=0.016), as well as serum potassium (median ΔK15mg -0.3±0.2 mEq/L vs ΔK10mg 0.10±0.18 mEq/L, p=0.011). No differences were found in Δcholesterol (total, HDL and non-HDL), liver or kidney function.

CONCLUSIONS: In this small cohort of healthy male volunteers, we demonstrated that GC treatment is associated with a worsening of insulin sensitivity through a dose-dependent effect. In addition, the decrease of serum potassium underpin the dose-dependent mineralocorticoid activity of GC. Further studies are needed to confirm our findings in larger cohort of patients.

Society for Endocrinology

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.